AtriCure releases transcript of Q2 2026 earnings call

AtriCure’s Q2 2026 earnings call drew CEO Michael Carrel, CFO Angela Wirick, IR adviser Marissa Bych, and analysts from Piper Sandler, BTIG, Canaccord, JPMorgan, Needham, Citizens JMP, Freedom, and Oppenheimer.

• Q2 revenue was $153.6 million, up 12.8%.
• Adjusted EBITDA was $27.3 million.
• Net income was $9 million.
• Gross margin was 77.2%.

AtriCure raised its 2026 outlook:

• Revenue: $602 million-$610 million
• Adjusted EBITDA: $85 million-$89 million
• EPS: $0.05-$0.13
• Adjusted EPS: $0.24-$0.32

BoxX-NoAF trial passed 500 patients, with a target of 960 by year-end. Data readouts are expected in , and a PMA submission is planned with about a .